Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22336919 | 0.80 | ALDH1A1 (0.48) | ALDH1A1CHRNB2CHRNB4CHRNA4LTA4H | |
| SCHEMBL21554075 | 0.74 | CHRNB2 (0.43) | ALDH1A1CHRNB2CHRNB4CHRNA4PAOX | |
| SCHEMBL22851385 | 0.73 | ALDH1A1 (0.63) | ALDH1A1PAOX | |
| SCHEMBL20176156 | 0.72 | CHRNB2 (0.41) | ALDH1A1CHRNB2CHRNB4CHRNA4PAOX | |
| SCHEMBL25183111 | 0.67 | ALDH1A1 (0.48) | ALDH1A1CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL25658866 | 0.66 | ALDH1A1 (0.47) | ALDH1A1CHRNB2CHRNB4CHRNA4PAOX | |
| SCHEMBL408247 | 0.66 | ALDH1A1 (0.56) | ALDH1A1CHRNB2CHRNB4CHRNA4HTT | |
| SCHEMBL4616554 | 0.64 | ALDH1A1 (0.54) | ALDH1A1CHRNB2CHRNB4CHRNA4PAOX | |
| SCHEMBL25339617 | 0.64 | ALDH1A1 (0.60) | ALDH1A1CHRNB2CHRNB4CHRNA4HTT | |
| SCHEMBL131476 | 0.64 | ALDH1A1 (0.74) | ALDH1A1CHRNB2CHRNB4CHRNA4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | ALDH1A1 1046/4885CHRNB2 3654/4885CHRNB4 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.